<DOC>
	<DOCNO>NCT00057811</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine rituximab rasburicase combination chemotherapy treat young patient newly diagnose advanced B-cell leukemia lymphoma . Monoclonal antibody rituximab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining one drug rituximab may kill cancer cell . Chemoprotective drug rasburicase may protect kidney cell side effect chemotherapy .</brief_summary>
	<brief_title>Rituximab , Rasburicase , Combination Chemotherapy Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity addition rituximab induction chemotherapy comprise vincristine , methylprednisolone , methotrexate , leucovorin calcium , cyclophosphamide , doxorubicin ( COPADM ) [ COMRAP ] consolidation chemotherapy child newly diagnose FAB prognostic group B group C leukemia lymphoma treat LMB/FAB therapy . II . Determine toxicity addition rasburicase reduction phase comprise cyclophosphamide , vincristine , prednisone methylprednisolone , methotrexate , leucovorin calcium ( COP-R ) patient . III . Determine incidence tumor lysis syndrome , renal complication , use assist renal support ( i.e. , dialysis hemofiltration ) COP-R reduction phase first induction phase COPADM COMRAP patient . IV . Determine response rate patient treat COMRAP incorporate LMB/FAB therapy . V. Assess minimal residual disease patient COMRAP therapy incorporate LMB/FAB therapy . OUTLINE : This multicenter study . Patients stratify accord FAB prognostic group ( B v C ) treat group classification . FAB GROUP B TREATMENT I ( first 6 patient ) : REDUCTION THERAPY : Patients receive COP-R regimen comprise cyclophosphamide IV 15 minute , vincristine IV , methotrexate hydrocortisone intrathecally ( IT ) day 0 ; rasburicase* IV 30 minute every 12 hour day 0 1 daily day 2-4 ( patient exhibit hyperuricemia clinical suspicion B-cell non-Hodgkin 's lymphoma B-cell acute lymphocytic leukemia also receive rasburicase day -3 , -2 , -1 ) ; leucovorin calcium IV orally every 12 hour day 1 3 ; prednisone ( PRED ) methylprednisolone ( MePRDL ) IV ( orally ) day 0-6 . Patients critical proceed may receive another course reduction therapy . NOTE : *Patients G6PD deficiency receive rasburicase reduction therapy . INDUCTION THERAPY : Patients le 20 % tumor reduction follow group C induction phase ( describe ) . Patients least 20 % tumor reduction receive 1 course COPADM regimen : vincristine IV methotrexate IV 4 hour day 0 ; PRED MePRDL IV ( orally ) day 0-7 ; leucovorin calcium IV orally every 6 hour 12 dos day 1-3 ; doxorubicin IV 30-60 minute day 1 ; cyclophosphamide IV 15 minute every 12 hour day 1-3 ; methotrexate IT hydrocortisone IT day 1 5 ; filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 6 continue blood count recover . Patients receive second part induction therapy peripheral blood count recover few 16 day first part induction therapy . Patients receive 1 course COMRAP regimen comprise rituximab IV day -2 0 COPADM first part induction therapy . CONSOLIDATION THERAPY : Patients receive CYM-RM regimen comprise rituximab IV methotrexate IV 4 hour day 0 ; leucovorin calcium IV orally every 6 hour 12 dos day 1-3 ; cytarabine IV 24 hour daily day 1-5 ; hydrocortisone IT day 1 6 ; methotrexate IT day 1 ; cytarabine IT day 6 . After full recovery consolidation therapy , patient residual mass undergo surgical excision biopsy . Patients histology positive tumor ( even completely resect ) proceed Group C consolidation therapy ( describe ) . Patients histology negative tumor proceed Group B maintenance therapy . MAINTENANCE THERAPY : Patients receive COPADM regimen comprise vincristine IV methotrexate IV 4 hour day 0 ; PRED MePRDL IV ( orally ) day 0-7 ; doxorubicin IV 30-60 minute , cyclophosphamide IV 30 minute day 1 2 ; methotrexate IT hydrocortisone IT day 1 ; leucovorin calcium IV orally every 6 hour day 1-3 ( 12 dos ) . TREATMENT II ( 44 patient ) : REDUCTION THERAPY : Patients receive COP-R regimen treatment I . INDUCTION THERAPY : Patients receive 2 course COMRAP regimen second induction treatment I . CONSOLIDATION THERAPY : Patients receive CYM-RM regimen treatment I . MAINTENANCE THERAPY : Patients receive COPADM regimen treatment I. FAB GROUP C : TREATMENT I ( first 3 patient ) : REDUCTION THERAPY : Patients receive COP-R regimen group B treatment I , addition triple intrathecal therapy ( TIT ) comprise methotrexate , hydrocortisone , cytarabine day 0 , 2 , 4 . INDUCTION THERAPY : Patients receive 2 course COPADM regimen group B treatment I , addition TIT day 1 , 3 , 5 . Patients group C biopsy-proven disease induction therapy protocol therapy treat discretion investigator . CONSOLIDATION THERAPY : CNS-POSITIVE DISEASE : Patients receive 2 course CYVE-RM regimen comprise rituximab IV methotrexate hydrocortisone IT day 0 ; cytarabine IV 12 hour day 0-4 ; high-dose cytarabine IV 3 hour etoposide IV 2 hour day 1-4 ; G-CSF SC day 6-20 . During first course , patient also receive HD-MTX IV 4 hour day 17 ; TIT day 18 ; leucovorin calcium IV orally every 6 hour day 18-21 ( 12 dos ) . CNS-NEGATIVE DISEASE : Patients receive CYVE-RM regimen without intrathecal therapy , HD-MTX , leucovorin calcium . After full recovery consolidation therapy , patient residual mass undergo surgical excision biopsy . Patients achieve complete remission consolidation therapy consider treatment failure . MAINTENANCE THERAPY ( course last 28 day ) : COURSE M1 : Patients receive vincristine IV high-dose methotrexate IV 4 hour day 0 ; PRED MePRDL IV ( orally ) day 0-7 ; doxorubicin IV 30-60 minute TIT day 1 ; cyclophosphamide IV 30 minute day 1 2 ; leucovorin calcium IV orally every 6 hour day 1-4 ( 12 dos ) . COURSE M2 : Patients receive etoposide IV 90 minute day 0-2 cytarabine SC every 12 hour day 0-4 . COURSE M3 : Patients receive vincristine IV day 0 ; cyclophosphamide IV 30 minute day 0 1 ; PRED MePRDL IV ( orally ) twice daily day 0-7 ; doxorubicin IV 30-60 minute day 0 ( first dose cyclophosphamide ) . COURSE M4 : Patients receive etoposide cytarabine course M2 . TREATMENT II ( 37 patient ) : REDUCTION THERAPY : Patients receive 2 course COP-R regimen group C treatment I . INDUCTION THERAPY : Patients receive COMRAP regimen comprise rituximab IV , vincristine IV , HD-MTX IV 4 hour day 0 ; PRED MePRDL IV ( orally ) day 0-7 ; leucovorin calcium IV orally cyclophosphamide IV 15 minute day 1-3 ; doxorubicin IV 30-60 minute day 1 ; TIT day 1 , 3 , 5 ; G-CSF SC day 6-20 . CONSOLIDATION THERAPY : CNS-positive disease : Patients receive CYVE-RM regimen plus HD-MTX group C treatment I . Patients receive CYVE-RM second course . CNS-NEGATIVE DISEASE : Patients receive CYVE-RM regimen group C treatment I . MAINTENANCE THERAPY : Patients receive maintenance therapy group C treatment I . Patients follow every 3-6 month 1 year every 6 month 5 year</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Leukemia , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Newly diagnose mature Blineage ( CD20positive ) leukemia lymphoma REAL classification 1 follow subtypes : Diffuse large cell lymphoma Burkitt 's lymphoma Highgrade Bcell lymphoma ( Burkittlike ) No Bcell anaplastic large cell Ki1 positive lymphoma Blymphoblastic lymphomas One follow FAB prognostic group : Group B ( intermediate risk ) Group C ( high risk ) Bone marrow involvement least 25 % blast and/or CNS involvement meet 1 follow criterion : Any L3 blast cerebrospinal fluid Cranial nerve palsy ( explain extracranial tumor ) Clinical spinal cord compression Isolated intracerebral mass Parameningeal extension ( cranial and/or spinal ) Hepatitis B status know Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No known history congenital immune deficiency and/or laboratory evidence acquire immune deficiency No know G6PD deficiency ( receive rasburicase ) No prior malignancy treat systemic chemotherapy alkylator anthracycline therapy No prior chemotherapy At least 1 week since prior steroid except emergency steroid initiate within 72 hour study entry No prior radiotherapy except emergency radiotherapy initiate within 72 hour study entry No concurrent radiotherapy No prior solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>